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Introduction
Colorectal cancer is the second leading cause of cancer deaths in the United States and the third most common malignant neoplasm worldwide. 1, 2 The development of colorectal cancer is driven by various factors such as genetic mutations, epigenetic abnormalities, and cancer-associated inflammation, [3] [4] [5] [6] which has emerged as the seventh hallmark of cancer. 7, 8 Studies have shown that the risk of colorectal cancer development in patients with inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn disease, is much higher than that in the general population. [9] [10] [11] [12] IBD is thought to result from a breakdown at the epithelial barrier, followed by inappropriate responses to microbial products and chronic inflammation in a genetically susceptible host. The cumulative risk of malignancy can be as high as 40% after 40 y of chronic IBD. Because of the increased risk of colitis-associated cancer (CAC), surveillance colonoscopy has become the standard method to detect dysplasia in individuals with ulcerative colitis. However, it has been estimated that only 20-50% of colonic neoplasms are detected during routine colonoscopy. 13 Therefore, antiinflammatory chemopreventive interventions for this high-risk population are urgently needed.
Inflammasomes are multiprotein complexes that serve as a platform for CASP1/caspase 1 activation and proinflammatory cytokine IL1B (interleukin 1, β) maturation. Thus, inflammasomes have a crucial role in host defense against infection as well as various autoinflammatory conditions. 14 Although a number of inflammasomes have been described, the NLRP3 (NLR family, pyrin domain containing 3) inflammasome is the most extensively studied. Indeed, NLRP3 inflammasome plays an important role in several inflammatory disorders including IBD. 15 NLRP3 inflammasome is triggered by a variety of stimuli, including infection, tissue damage, and metabolic dysregulation, and then activated through an integrated cellular signaling pathway. Many regulatory mechanisms have been identified to attenuate NLRP3 inflammasome signaling at multiple steps. Among them, induction of selective mitochondrial autophagy (known as mitophagy), which results in selective clearance of damaged mitochondria in cells, can negatively regulate NLRP3 inflammasome activation. 16, 17 Therefore, a better understanding of the mutual regulation of inflammasomes and autophagy will be essential for discovering new therapeutics for chronic inflammatory diseases.
Andrographolide is a natural diterpenoid that is the major constituent of Andrographis paniculata, which is a plant indigenous to Southeast Asian countries that has been used as an herbal medicine in China for thousands of years. Andro has been reported to exert antibacterial, anti-asthmatic, antiviral, and neuroprotective activities, [18] [19] [20] and sulfonated Andro (Xi-YanPing Injection) has been approved as a drug for years in China for the treatment of various inflammatory conditions including respiratory infections, bacterial dysentery, and fever. Previously, Andro was reported to inhibit tumor growth in mice at a relatively high dose (about 200 mg/kg), 21 suggesting that a direct antitumor effect might be less involved in its activity. However, the effect of Andro on colitis-associated tumor development has not yet been investigated.
In the present study, we demonstrated that the natural small molecule Andro significantly protected mice against CAC in the mouse model of azoxymethane (AOM)-dextran sulfate sodium (DSS) through inhibiting NLRP3 inflammasome activation in macrophages. Further study showed that Andro triggered mitophagy through inhibiting the PIK3CA-AKT1-MTOR-RPS6KB1 pathway, leading to a reversed mitochondrial membrane potential collapse, which inactivated the NLRP3 inflammasome. The findings obtained in this study suggest that the prevention of CAC results from Andro-driven mitophagymediated NLRP3 inflammasome inhibition. Accordingly, these findings may help direct clinical decisions regarding the use of Andro in patients with IBD, ultimately reducing the risk of CAC.
Results

Andro prevents tumorigenesis in a colitis-associated colorectal cancer model
To determine whether Andro directly decreases the incidence of colitis-associated cancer, we generated an AOM-DSS mouse model for colitis-associated colonic tumorigenesis by injecting mice with procarcinogenic AOM followed by 3 cycles of oral DSS administration. Andro was well tolerated, as 100% of the mice survived the treatment. The body weight of the mice was monitored throughout the experiment. The mice lost weight substantially following each exposure to 2.5% DSS and subsequently regained the weight while being maintained on water. In the group of Andro treatment, the mice had a reduced weight loss due to each DSS exposure and recovered more quickly than mice in the AOM-DSS group (Fig. 1A) . The mice were sacrificed on d 95 following induction. The incidence of tumors was 100% in all mice. However, fewer and smaller tumors were observed in the Andro-treated group (Fig. 1B and C) . The average number of tumors per mouse in the AOM-DSS group was more than 2 times higher than that in the 15 mg/kg Androtreated group (Fig. 1D) . The tumor size was reduced by Andro in a dose-dependent manner ( Fig. 1E and F) . Correspondingly, the average tumor load, which represents the sum of the diameters of all tumors in a given mouse, was significantly decreased in the Andro-treated group (Fig. 1G) . Moreover, protein expressions of PCNA and p-STAT3 ( Fig. 2A-C) , and mRNA expressions of Hif1a and Vegfa (Fig. 2D ) in colonic tissue were remarkably downregulated by Andro treatment. Together, these results indicate that Andro administration reduces colitis-associated tumorigenesis in mice.
Andro attenuates inflammation in a colitis-associated colorectal cancer model
In addition to the reduced colitis-associated tumorigenesis in AOM-DSS-treated mice, we found that the inflammation level was deeply decreased by Andro administration. Phosphorylation of RELA/p65, the subunit of the key inflammatory transcription factor NFKB/NF-κB, was markedly reduced by Andro as shown by immunochemistry and western blotting ( Fig. 2A-C) . Expression of proinflammatory cytokines such as Tnf/TNF-α (tumor necrosis factor), Il17a (interleukin 17A), and Il6 (interleukin 6) was also significantly suppressed (Fig. 2E) . In addition, Andro remarkably inhibited the expression of PTGS2/ COX2 ( Fig. 2A and E) , which is an important mediator of the inflammatory process. 22 To determine whether Andro could inhibit tumors that had already formed in the AOM-DSSinduced tumorigenesis model, Andro was given to the mice from d 50 to d 120. Tumors had significantly formed at d 50, and Andro given to mice starting at this time point had only a minor effect on tumor growth (Fig. S1) . Furthermore, we found that Andro at the dose of 15 mg/kg did not inhibit transplanted mouse colon carcinoma CT26 cell growth in mice (Fig. S2) . Though a previous study reported that Andro inhibited tumor growth, the dose they used was as high as 100-200 mg/kg. 21 Hence, the data obtained here strongly suggest that Andro prevents colitisassociated tumorigenesis by inhibiting inflammation rather than directly killing tumor cells.
Andro ameliorates DSS-induced experimental colitis in mice
Because Andro showed a strong effect in reducing inflammation in the AOM-DSS model, we hypothesized that Andro might prevent tumorigenesis in the AOM-DSS model by inhibiting inflammation. Next, we examined the effect of Andro on DSS-induced experimental colitis in mice. After being challenged with DSS in their drinking water, the mice showed an increasing severity of symptoms, including dramatic body weight loss, rectal bleeding, and diarrhea. Administration of Andro at 2.5 and 5 mg/kg significantly attenuated body weight loss during disease progression, and Andro was more potent than the positive control sulfasalazine administered at a dose of 200 mg/kg (Fig. 3A) . The disease activity index, which is a clinical parameter that reflects the severity of weight loss, rectal bleeding, and stool consistency, was dose-dependently reduced in the Andro-treated mice relative to the DSS group (Fig. 3B) . Moreover, Andro alleviated the shortening of the colon caused by DSS treatment (Fig. 3C and D) . H&E staining and histological analysis revealed severe pathological changes, including mucosal damage, necrosis, and infiltration of inflammatory cells such as neutrophils and monocytes in colon samples of DSS-treated mice. Andro displayed a significant improvement of these pathological changes in a dosedependent manner ( Fig. 3E and F) . In addition, assessment of myeloperoxidase (MPO) activity in the colons of mice showed a significant suppressive effect of Andro compared with the DSStreated group (Fig. 3G) .
Mice with DSS-induced colitis exhibited a cytokine profile similar to that in human IBD, including overproduction of proinflammatory cytokines such as TNF, IL1B, IFNG, and IL17A. The mRNA expression of Tnf, Il1b, Ifng, and Il17a and protein expression of TNF, IL1B, IFNG, and IL17A in the colon were remarkably increased after the DSS challenge. Andro significantly suppressed the upregulation of these inflammatory cytokines ( Fig. 3H and I) . NFKB plays an important role in IBD by transcriptional induction of various genes involved in inflammation. 23 We found that Andro treatment markedly reduced the phosphorylation of RELA in the colons of DSS-treated mice, as detected by western blotting and immunohistochemistry ( Fig. 3J and K) .
NLRP3 inflammasome inhibition contributes to the antiinflammatory effect of Andro
To investigate the mechanism of Andro-mediated protection from murine colitis, we examined the NLRP3 inflammasome activation in macrophages both in vivo and in vitro. Results from Figure 4A showed that Andro treatment (5 mg/kg) prominently inhibited CASP1 activation in vivo as compared with vehicle treatment in DSS-treated mice. In addition, very few infiltrating macrophages were detected in the Andro-treated group (Fig. 4B) . Next we examined the direct effect of Andro on inflammasome activation in cultured macrophages in vitro. As a result, Andro produced a concentration-dependent inhibition of IL1B secretion from lipopolysaccharide (LPS)-treated human monocytic THP-1 cells and murine bone marrow-derived macrophage (BMDM) by the ELISA assay ( Fig. 5A ) without affecting the survival of macrophages (Fig. S3) . In addition, detection of the p17 fragment of mature IL1B further confirmed the ELISA results (Fig. 5B) . Moreover, we found that activation of CASP1 (as indicated by the presence of the cleaved form and enzyme activity) was significantly inhibited by Andro ( Fig. 5B and C) . Furthermore, immunoprecipitation and immunofluorescence analysis showed that the process of NLRP3 inflammasome formation was also interrupted by Andro ( Fig. 5D and E) .
Andro-induced mitophagy is responsible for inhibition of the NLRP3 inflammasome and amelioration of murine models for colitis and CAC NLRP3 secondary signal activators, such as ATP, induce mitochondrial dysfunction. (Fig. 6A ) and mitochondria fragmentation (Fig. 7A) , as well as swollen mitochondria with cristae disruption (Fig. 7B , white arrows). We found that in the Andro-treated group, the damaged mitochondria were localized near a lysosome in the autophagolysosome (Fig. 7B , LPS+ATP+Andro group, green arrow) and was surrounded by a double membrane (Fig. 7B , LPS+ATP+Andro group, blue arrows), suggesting that Andro triggers mitophagy. In addition, western blot and immunofluorescence staining showed that Andro induced the localization of the phagophore and autophagosomal marker microtubule-associated protein 1 light chain 3/LC3 to mitochondria (Fig. 6E and F) . These results further suggest that mitophagy is triggered by Andro. To further confirm this phenomenon, we analyzed the expression of LC3. An increase in LC3-labeled vacuole formation in BMDM cells occurred after treatment with 30 μM Andro (Fig. 6C and F) . Moreover, Andro caused the conversion of LC3-I to LC3-II in a dose-and timedependent manner in LPS-primed THP-1 cells (Fig. 6B and D) . Furthermore, we confirmed that Andro inhibited the PIK3CA-AKT1-MTOR-RPS6KB1 pathway ( Fig. 6D) but had little effect on the MAPK1/ERK2-MAPK3/ERK1-mediated pathway (Fig. S4) . As expected, Andro-induced inhibition of CASP1 activation and IL1B release was reversed by BECN1/beclin 1 silencing (Fig. 8A) or autophagy inhibitors 3-MA, chloroquine (CQ), bafilomycin A 1 (Baf A1), and NH 4 Cl (Fig. 8B and C) . Finally, Andro further enhanced the LC3-II level in cells treated with CQ (Fig. 8D) , which suggests that the increased autophagic markers (LC3 puncta and LC3-II) in Andro-treated cells are due to increased autophagic flux rather than suppression of the late maturation and degradation stage of autophagy.
To provide evidence linking mitophagy, inflammasomes, and the in vivo outcome of Andro, the autophagy inhibitor CQ was used in the murine models for experimental colitis and CAC to confirm the action of Andro. We found that the ameliorative effect of Andro on murine experimental colitis (Fig. 9A-E) and CAC ( Fig. 9F and G) was significantly blocked by CQ.
This blockage was closely related to inhibition of autophagy and aggravation of inflammasome activation ( Fig. 9H and I) . These results strongly support mitophagy as one of the main mechanisms of Andro-mediated inhibition of the NLRP3 inflammasome both in vitro and in vivo.
Discussion
It is now widely accepted that chronic nonresolving inflammation contributes to the initiation, promotion, and progression of tumor development. 26 One of the best clinically characterized examples of the association between inflammation and carcinogenesis is the development of colitis-associated cancer in patients suffering from ulcerative colitis, which is a common form of inflammatory bowel disease. 9 Therefore, new antiinflammatory interventions for the prevention of inflammation-associated cancer are desperately needed. 8, 26 We report herein that the small molecule Andro protects mice against CAC by reducing IL1B release from macrophages via mitophagy-mediated NLRP3 inflammmasome inhibition.
Ulcerative colitis is an idiopathic IBD characterized by chronic and recurring inflammation. High levels of the proinflammatory cytokine IL1B secreted by macrophages of the lamina propria from the colon are detected in cases of active colitis and are correlated with the severity of inflammation. [27] [28] [29] [30] [31] IL1B modulates the functions of dendritic cells, macrophages, neutrophils, and T cells. 32, 33 In particular, IL1B is also involved in the differentiation of Th17 cells. 31, 34 IL1B is translated as an inactive 31-kDa precursor (pro-IL1B) after toll-like receptor stimulation (signaling I), and this precursor is cleaved to its activated 17-kDa form by the NLRP3 inflammasome-activated CASP1 (signaling II). 35 Although the NLRP3 inflammasome has been the most extensively studied, our understanding of its function has proven the most elusive.
14 For instance, the role of the NLRP3 inflammasome in colitis and CAC is controversial. Several lines of data from gene-deleted mouse models showed that the NLRP3 inflammasome protects against experimental colitis 36 and colitis-associated tumorigenesis, 37 whereas other groups demonstrated that NLRP3-PYCARD-CASP1-mediated maturation of IL1B is essential for DSS-induced experimental colitis and nlrp3 −/− mice develop a less severe colitis than wildtype mice. [38] [39] [40] [41] Bauer et al. pointed out that these contradictions might result from the different composition of the intestinal microflora. 41 Unlike the controversies resulting from genedeleted mouse models, IL18 neutralization, 42, 43 or chemical CASP1 inhibitor 44, 45 treatment effectively reduce severity in murine colitis. Therefore, inhibition of CASP1-mediated IL1B secretion may serve as a useful therapeutic option for patients with IBD. It has been reported that Andro can decrease IL1B production by affecting signaling I via inhibiting RELA activation. 48, 49 Our results also confirmed this inhibitory effect of Andro on phosphorylated RELA in mice with CAC ( Fig. 2A-C) and with DSS-induced colitis ( Fig. 3J and K) , and in LPS-activated THP-1 cells (Fig. S5) . In addition to the effect on signaling I, in the present study, we found that Andro disrupted signaling II and inhibited CASP1 activation ( Fig. 4A; Fig. 5C and D) , which resulted in a reduction of IL1B secretion in vivo (Fig. 3I ) and in vitro (Fig. 5A and B) . CASP1 activation is tightly controlled by signaling II. When activated by diverse stimuli such as signaling from mitochondria (e.g., reactive oxygen species and mitochondrial DNA), 50, 51 NLRP3 proteins polymerize and bind to the PYCARD adaptor, which promotes the recruitment of pro-CASP1 through CARD-CARD interactions. Pro-CASP1 then clusters and autocleaves to form the activated CASP1 p10-p20 tetramer, which triggers CASP1-dependent processing of pro-IL1B and pro-IL18. 24, 25, 52 Because of the negative regulatory role of mitophagy in the NLRP3 inflammasome activation, 24, 25, 50 mitochondria become a useful target for inflammation control. Our study found that Andro treatment effectively prevented ATP-induced collapse of the mitochondrial membrane potential (Fig. 6A) . Given that autophagy regulated NLRP3-dependent inflammation by preserving mitochondrial integrity, 53 we found that Andro triggered mitophagy through the PIK3CA-AKT1-MTOR-RPS6KB1 pathway (Fig. 6D) , thereby inhibiting CASP1 activation. But still the detailed molecular mechanisms for Andro's effect on mitophagy remain to be further investigated.
Previous studies suggested that NLRP3 inflammasome activity was negatively regulated by mitophagy and positively regulated by reactive oxygen species. 25 Here we show that Andro-driven mitophagy leads to the reduction of damaged mitochondria, which in turn inactivates the NLRP3 inflammasome and ameliorates colitis and CAC in mice. Our conclusions were based on the following observations: First, Andro-mediated inhibition of CASP1 activation and IL1B release in macrophages was significantly blocked by BECN1 silencing (Fig. 8A) or by the autophagy inhibitors 3-MA, CQ, Baf A1, and NH 4 Cl (Fig. 8B and C) in vitro. Second, the autophagy inhibitor CQ remarkably abolished the ameliorative effect of Andro on DSS-induced colitis (Fig. 9A-E) and AOM-DSS-induced CAC (Fig. 9F and G) in mice through inhibiting autophagy. Finally, Andro-induced inhibition of IL1B secretion (Fig. 9D) and NLRP3 inflammasome activity ( Fig. 9H and  I ) in macrophages was also reversed by CQ treatment in vivo. These data strongly suggest that andrographolide-driven mitophagy-mediated inhibition of the NLRP3 inflammasome is responsible for the amelioration of experimental colitis and colitis-associated tumorigenesis in mice. Together with the data on RELA as shown in Figure 2, Figure 3 , and Figure  S5 , we conclude that the inhibition of both signaling I (one of the NFKB functions) and signaling II of the inflammasome pathway is important for the effects of Andro on colitis and CAC. It should be emphasized that there are few reports on the mitophagy-mediated inhibition of the NLRP3 inflammasome by a small molecule. The effect of Andro reported here is distinct from other known antiinflammatory drugs, such as nonsteroidal antiinflammatory drugs (NSAIDs), which may provide a new choice for the treatment of colitis and its related cancers.
Recently, Andro has been reported to induce autophagic cell death in liver cancer Huh-7 cells through the disruption of the mitochondrial transmembrane potential and elevation of reactive oxygen species. 54 Conversely, Zhou et al. reported that Andro sensitized human cancer cells to cisplatin-induced apoptosis via suppression of autophagosome-lysosome fusion. These findings suggest that Andro can induce or inhibit autophagy in various kinds of cells via different mechanisms. We speculate that these discrepancies may result from the use of different cell types or different Andro concentrations and incubation times.
In conclusion, our results in this study provide strong evidence for the chemopreventive activity of Andro against colitis-associated colorectal cancer in mice through inhibiting inflammation. The mechanism underlying the activity of Andro involves PIK3CA-AKT1-MTOR-RPS6KB1 pathwaymediated mitophagy-dependent inactivation of the NLRP3 inflammasome, thus leading to decreased NLRP3-PYCARD-CASP1-mediated IL1B secretion from macrophages. Our data presented here may help guide decisions regarding the use of (B) LPS-primed THP-1 cells were treated with 30 μM Andro for 1 h, followed by 1 h incubation with 5 mM ATP. Cells were collected for transmission electron microscopy assay. White arrow, normal mitochondria; red arrow, swollen mitochondria with disrupted cristae; blue arrow, a double membrane; green arrow, the damaged mitochondria were localized near a lysosome in the autophagolysosome. Data shown in (A and B) are representative of 3 experiments. Andro, andrographolide.
Andro as an anti-inflammatory agent in IBD patients, ultimately reducing the risk of CAC.
Materials and Methods
Animals C57BL/6 mice, 6-8 wk old, were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China). They were maintained with free access to pellet food and water in plastic cages at 21 ± 2 °C and kept on a 12 h light/ dark cycle. Animal welfare and experimental procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, the United States) and the related ethical regulations of our university. All efforts were made to reduce the number of animals used and to minimize animals' suffering.
Cell culture
The human monocytic THP-1 cell line was purchased from the Shanghai Institute of Cell Biology (Shanghai, China) and cultured at 37 °C in a 5% (v/v) CO 2 atmosphere. Peritoneal macrophages were harvested from the peritoneal cavity of C57BL/6 mice and purified by adherence to tissue culture plastic. 56 Bone marrow cells were isolated from C57BL/6 mice and cultured with DMEM supplemented with 10% fetal bovine serum (Gibco, 10100147) and 20 ng/ml recombinant murine M-CSF (PeproTech, 315-02). Culture fluid was exchanged with fresh culture medium every 3 d. Under these conditions, an adherent macrophage monolayer was obtained at d 7. Cells were harvested and seeded on 24-well plates. After culturing for 6 h without M-CSF, the cells were used for the experiments as bone marrow-derived macrophages (BMDM). Fractionation Kit (ab65320) was purchased from Abcam. The GTVisin TM anti-mouse/anti-rabbit immunohistochemical analysis kit was purchased from Shanghai Gene Company Ltd. The shRNA scramble and shRNA BECN1 were purchased from Shanghai NeuronBiotech Company. All other chemicals were obtained from Sigma-Aldrich.
Induction and treatment of colitis-associated cancer and colitis
To induce colitis-associated cancer (CAC), mice were injected intraperitoneally (i.p.) with a single dose (7.5 mg/ kg) of AOM followed by 3 cycles of 2.5% DSS given in the drinking water for 5 d. 57 Andro was administered through i.g. (intragastrically) daily at the indicated dose during the interval between DSS cycles. Mice were sacrificed on d 95 after CAC induction. The entire colon and rectum were processed for histopathological examination. Acute colitis was induced by giving 2.5% DSS in the drinking water for 7 d. Andro was administered through i.p. injection daily at the indicated dose for 10 d. Body weight, stool consistency, and the presence of gross blood in feces and at the anus were observed every day. The disease activity index was calculated by assigning well-established and validated scores. Briefly, the following parameters were used for calculation: a) diarrhea (0 points = normal, 2 points = loose stools, 4 points = watery diarrhea); b) hematochezia (0 points = no bleeding, 2 points = slight bleeding, 4 points = gross bleeding).
Histological analysis, immunohistochemistry, and immunofluorescence
Colonic sections from mice were obtained for H&E staining and analyzed by a pathologist using a light microscope (Olympus). For immunohistochemistry or immunofluorescence staining, the sections were deparaffinized, rehydrated, and washed in 1% PBS-Tween 20, and then treated with 2% hydrogen peroxide, blocked with 3% goat serum (Life Technology, 16210-064) and incubated for 2 h at room temperature with specific primary antibodies. For immunofluorescence of ITGAM/CD11b, the slides were incubated with ITGAM-FITC (eBioscience, 11-0112) for 1 h and then counter-stained with DAPI for 5 min. For immunofluorescence of LC3, the protocol has been reported previously. 58 For immunohistochemistry, the slides were incubated with streptavidin-HRP (Shanghai Gene Company, GK500705) for 40 min, then stained with DAB (Shanghai Gene Company, GK500705) substrate and counter-stained with hematoxylin. Images were acquired by confocal laser-scanning microscopy (Olympus FV1000).
Cytokine analysis by ELISA Colons from mice in each group were homogenized with lysis buffer to extract total protein. The homogenate was centrifuged at 12 000 g at 4 °C for 15 min. The amount of total extracted protein was determined by BCA TM protein assay kit (Pierce, 23225). The commercial ELISA kits (Dakewe, Beijing) of murine IFNG , murine IL17A (12-2170), murine TNF (12-2720), murine IL1B (12-2012) and human IL1B (12-1012) were used to measure the cytokine levels.
Real-time PCR Real-time PCR was performed as follows: RNA samples were reverse transcribed to cDNA and subjected to quantitative PCR, which was performed with the BioRad Real-Time PCR Detection System (Bio-Rad, CFX Connect TM ) using iQ TM SYBR ® Green Supermix (Bio-Rad, 1708880), and threshold cycle numbers were obtained using BioRad CFX Manager software. The program for amplification was 1 cycle of 95 °C for 2 min followed by 40 cycles of 95 °C for 10 s, 60 °C for 30 s, and 95 °C for 10 s. The primer sequences used in this study are listed in the Supplementary data.
Western blot and transmission electron microscopy assay The protocols for western blot and transmission electron microscopy assay have been reported previously. 58 
Coimmunoprecipitation assay
Cells were collected and lysized with lysis buffer (Beyotime company, P0013) on ice for 30 min and centrifuged at 12,000 g at 4 °C for 15 min. The supernatant fractions were collected and incubated with 1 μg of appropriate antibody at 4 °C overnight and precipitated with protein A/G-agarose beads (Santa Cruz, sc-2003) for another 4 h at 4 °C. The beads were washed with the lysis buffer 4 times by centrifugation at 1,000 g at 4 °C. The immunoprecipitated proteins were separated by SDS-PAGE and western blot was performed with the indicated antibodies.
Statistical analysis Data are expressed as mean ± SEM. Student's t test and oneway ANOVA test were used for statistical analyses of the data. Cases in which P values were < 0.05 or < 0.01 were considered statistically significant.
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